Biocon's Evaluation After Acquisitions: An Inflection Point?

Biocon, a pharmaceutical company, has grown a lot recently by buying other companies.

Its income has increased a lot in the last few years.

Although profits haven't grown as fast, the company is trying to improve this.

Biocon makes different types of medicines, including biosimilars and generics.

They also offer research services.

To pay for its growth, Biocon has taken on more debt and is now trying to reduce this debt by selling stocks to investors.

The company aims to become a major player in the pharmaceutical industry.

It remains to be seen if it will pay off in the end.

Some analysts think it is undervalued compared to its peers.